{
    "Symbol": "PCVX",
    "AssetType": "Common Stock",
    "Name": "Vaxcyte\u00a0Inc",
    "Description": "Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. The company is headquartered in Foster City, California.",
    "CIK": "1649094",
    "Exchange": "NASDAQ",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)",
    "Address": "353 HATCH DR, FOSTER CITY, CA, US",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2024-03-31",
    "MarketCapitalization": "8550199000",
    "EBITDA": "-507878016",
    "PERatio": "None",
    "PEGRatio": "None",
    "BookValue": "18.24",
    "DividendPerShare": "None",
    "DividendYield": "None",
    "EPS": "-4.29",
    "RevenuePerShareTTM": "0",
    "ProfitMargin": "0",
    "OperatingMarginTTM": "0",
    "ReturnOnAssetsTTM": "-0.206",
    "ReturnOnEquityTTM": "-0.298",
    "RevenueTTM": "0",
    "GrossProfitTTM": "-22995000",
    "DilutedEPSTTM": "-4.29",
    "QuarterlyEarningsGrowthYOY": "0",
    "QuarterlyRevenueGrowthYOY": "0",
    "AnalystTargetPrice": "103.14",
    "AnalystRatingStrongBuy": "5",
    "AnalystRatingBuy": "4",
    "AnalystRatingHold": "0",
    "AnalystRatingSell": "0",
    "AnalystRatingStrongSell": "0",
    "TrailingPE": "-",
    "ForwardPE": "-",
    "PriceToSalesRatioTTM": "-",
    "PriceToBookRatio": "5.41",
    "EVToRevenue": "-",
    "EVToEBITDA": "-14.43",
    "Beta": "0.972",
    "52WeekHigh": "87.71",
    "52WeekLow": "44.2",
    "50DayMovingAverage": "76.42",
    "200DayMovingAverage": "65.84",
    "SharesOutstanding": "108795000",
    "DividendDate": "None",
    "ExDividendDate": "None"
}